A resolution designating July 15, 2021, as "National Leiomyosarcoma Awareness Day" and the month of July 2021 as "National Sarcoma Awareness Month".

Bill: 117-sres-298
Sponsor: full_name: Sen. Stabenow, Debbie [D-MI]
Introduced: 2021-07-13
Policy area: Health
Latest action: action_date: 2021-07-13
text: Referred to the Committee on the Judiciary. (text: CR S4857)

Summaries:
action_date: 2021-07-13
action_desc: Introduced in Senate
text: <p class="MsoNormal">This resolution designates July 15, 2021, as National Leiomyosarcoma Awareness Day and July 2021 as National Sarcoma Awareness Month. Sarcoma is a malignant cancer that arises from certain tissues, such as bone or muscle; leiomyosarcoma is a type of sarcoma that arises from smooth muscle tissue, most commonly originating in the uterus, stomach, intestine, or blood vessels.</p>

tv_txt: III 117th CONGRESS 1st Session S. RES. 298 IN THE SENATE OF THE UNITED STATES July 13, 2021 Ms. Stabenow submitted the following resolution; which was referred to the Committee on the Judiciary RESOLUTION Designating July 15, 2021, as National Leiomyosarcoma Awareness Day and the month of July 2021 as National Sarcoma Awareness Month .

Whereas sarcoma is a rare type of cancer that— (1) arises in the connective tissue of the body; and (2) accounts for approximately 1 percent of all newly diagnosed cancers; Whereas the National Institutes of Health designates sarcoma, which contains approximately 70 different subtypes, as a rare form of cancer; Whereas sarcomas are largely resistant to current chemotherapy agents, immunotherapy agents, and radiation therapies, posing a formidable challenge for researchers and specialists; Whereas sarcoma subtypes largely have not benefitted from immunotherapies because of the complexity of the DNA, genomes, and mutations associated with the many variations in the sarcoma subtype landscape; Whereas leiomyosarcoma (referred to in this preamble as LMS ) is a malignant, aggressive subtype of sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin that can metastasize to the bone, spine, brain, and liver; Whereas the National Institutes of Health classifies LMS, which encompasses at least 4 different LMS subtypes, as a rare disease, accounting for approximately 15 percent of all sarcomas; Whereas LMS primarily affects adults without regard to gender; Whereas, with respect to LMS— (1) research and clinical trials remain complicated; and (2) survival and longevity remain difficult; Whereas multidisciplinary care coordination teams, because of their expertise and experience, are critical to the health of sarcoma and LMS patients; Whereas sarcoma and LMS research will— (1) allow medical professionals to improve the quality of care for affected patients; (2) lead to better clinical outcomes; and (3) promote longer survival for patients; and Whereas increased education and awareness about sarcoma and LMS will contribute to the well-being of the communities of the United States: Now, therefore, be it

That the Senate— (1) designates July 15, 2021, as National Leiomyosarcoma Awareness Day ; (2) designates the month of July 2021 as National Sarcoma Awareness Month ; (3) recognizes the challenges faced by sarcoma and leiomyosarcoma patients; and (4) commends the dedication of organizations, volunteers, researchers, and caregivers across the United States working to improve the quality of life of sarcoma and leiomyosarcoma patients and their families.